Cited by 1,901Bariatric Surgery and OutcomesDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes

Open access
Schauer, Philip R., Bhatt, Deepak L., Kirwan, John P., Wolski, Kathy, Brethauer, Stacy A., Navaneethan, Sankar D., Aminian, Ali, Pothier, Claire E. +3 more·2014·New England Journal of Medicine

Abstract

BACKGROUND: In short-term randomized trials (duration, 1 to 2 years), bariatric surgery has been associated with improvement in type 2 diabetes mellitus. METHODS: We assessed outcomes 3 years after the randomization of 150 obese patients with uncontrolled type 2 diabetes to receive either intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy. The primary end point was a glycated hemoglobin level of 6.0% or less. RESULTS: The mean (±SD) age of the patients at baseline was 48±8 years, 68% were women, the mean baseline glycated hemoglobin level was 9.3±1.5%, and the mean baseline body-mass index (the weight in kilograms divided by the square of the height in meters) was 36.0±3.5. A total of 91% of the patients completed 36 months of follow-up. At 3 years, the criterion for the primary end point was met by 5% of the patients in the medical-therapy group, as compared with 38% of those in the gastric-bypass group (P<0.001) and 24% of those in the sleeve-gastrectomy group (P=0.01). The use of glucose-lowering medications, including insulin, was lower in the surgical groups than in the medical-therapy group. Patients in the surgical groups had greater mean percentage reductions in weight from baseline, with reductions of 24.5±9.1% in the gastric-bypass group and 21.1±8.9% in the sleeve-gastrectomy group, as compared with a reduction of 4.2±8.3% in the medical-therapy group (P<0.001 for both comparisons). Quality-of-life measures were significantly better in the two surgical groups than in the medical-therapy group. There were no major late surgical complications. CONCLUSIONS: Among obese patients with uncontrolled type 2 diabetes, 3 years of intensive medical therapy plus bariatric surgery resulted in glycemic control in significantly more patients than did medical therapy alone. Analyses of secondary end points, including body weight, use of glucose-lowering medications, and quality of life, also showed favorable results at 3 years in the surgical groups, as compared with the group receiving medical therapy alone. (Funded by Ethicon and others; STAMPEDE ClinicalTrials.gov number, NCT00432809.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1401329

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MNT education by registered dieticians is effective.

    “MNT education by registered dieticians is effective 10 , 11 (grade A: 95% agreement).”

    From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [11]

  • Blood pressure control is useful for suppressing the onset/progression of diabetic retinopathy in patients with type 2 diabetes.

    “Blood pressure control has been shown to be useful for suppressing the onset/progression of diabetic retinopathy in patients with type 2 diabetes 9 , 10 , 11 (grade A: 100% agreement).”

    From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [11]

  • SMBG is useful for patients with type 1 diabetes.

    “SMBG has been shown to be useful for patients with type 1 diabetes 9 , 10 , 11 and for patients with type 2 diabetes receiving insulin therapy 12 (grade A: 95% agreement).”

    From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [11]

  • Blood pressure control is effective in inhibiting the onset/progression of diabetic nephropathy.

    “Blood pressure control is shown to be effective in inhibiting the onset/progression of diabetic nephropathy 11 , 12 , 13 (grade A: 100% agreement).”

    From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [11]

  • Tight glycemic control, initiated early after the onset of diabetes, is effective in suppressing the risk of diabetic macroangiopathy.

    “Tight glycemic control, initiated early after the onset of diabetes, has been shown to be effective in suppressing the risk of diabetic macroangiopathy 10 , 11 (grade A: 95% agreement).”

    From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [11]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Brethauer, S. A., Navaneethan, S. D., Aminian, A., Pothier, C. E., Kim, E. S. H., Nissen, S. E., & Kashyap, S. R.
Affiliations
  • Brigham and Women's Hospital (US)
  • Cleveland Clinic (US)
Venue
New England Journal of Medicine
Published
2014-05-22
Volume
370
Issue
21
Pages
2002-2013
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2147872784
Cited by
1,901
References
28
Citations by year
2026: 35 · 2025: 56 · 2024: 83 · 2023: 117 · 2022: 105 · 2021: 157 · 2020: 157 · 2019: 146 · 2018: 206 · 2017: 243 · 2016: 243 · 2015: 236 · 2014: 107 · 2013: 3 · 2012: 2
FWCI
273.84
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Cleveland Clinic
  • Stryker
  • Amarin Corporation
  • Anthera
  • Medicines Company
  • Regado Biosciences
  • Eisai
  • Novo Nordisk
  • National Institutes of Health
  • Cereal Partners Worldwide
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK089547)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
bariatric surgery, type 2 diabetes, Roux-en-Y gastric bypass, sleeve gastrectomy, intensive medical therapy, glycemic control, HbA1c, obesity, weight loss, glucose-lowering medications, insulin use, quality of life, long-term outcomes, STAMPEDE trial, randomized controlled trials, surgical complications, body mass index
MeSH terms
Adult, Combined Modality Therapy, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Gastrectomy, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Obesity, Postoperative Complications, Quality of Life, Triglycerides, Gastric Bypass, Biomarkers, Weight Loss, Body Mass Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review